Recursion Pharmaceuticals (RXRX) Receivables - Other (2021 - 2026)

Recursion Pharmaceuticals (RXRX) has 6 years of Receivables - Other data on file, last reported at $5.2 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other fell 16.13% year-over-year to $5.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 16.13% YoY), and the FY2025 full-year result was $24.6 million, up 212.01% from the prior year.
• Receivables - Other for Q1 2026 stood at $5.2 million, down from $24.6 million in the prior quarter.
• Across five years, Receivables - Other topped out at $49.2 million in Q4 2024 and bottomed at $2.1 million in Q1 2023.
• The 5-year median for Receivables - Other is $6.2 million (2025), against an average of $10.5 million.
• The widest annual swing landed in 2023, when Receivables - Other slumped 81.9%; it then surged 1489.08% in 2024.
• A 5-year view of Receivables - Other shows it stood at $2.8 million in 2022, then increased by 12.39% to $3.1 million in 2023, then soared by 1489.08% to $49.2 million in 2024, then plunged by 49.87% to $24.6 million in 2025, then sank by 78.9% to $5.2 million in 2026.
• The last three Receivables - Other figures came in at $5.2 million (Q1 2026), $24.6 million (Q4 2025), and $5.6 million (Q3 2025), per Business Quant data.

Peer Comparison